Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 8:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 69 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Spasticity
Interventions
Phase 2; Low Dose MYOBLOC (15,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo, Phase 3; MYOBLOC, Phase 3; Placebo
Drug
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Downey, California • Boise, Idaho • Port Royal, South Carolina + 1 more
Conditions
Parkinson's Disease, Motor Symptoms, Akinesia, Hypomobility, Delayed Levodopa Onset
Interventions
APOKYN, L-dopa, Trimethobenzamide
Drug
Lead sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
Los Angeles, California • Reseda, California • Washington D.C., District of Columbia + 9 more
Conditions
Treatment Resistant Depression
Interventions
NV-5138, matched placebo
Drug
Lead sponsor
Navitor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bellevue, Washington
Conditions
Drooling
Interventions
Botulinum Toxin Type B (Myobloc), Matched placebo to Myobloc
Biological
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
18
States / cities
Scottsdale, Arizona • Northridge, California • Oxnard, California + 15 more
Conditions
Partial Epilepsy
Interventions
Oxcarbazepine XR
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 66 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
20
States / cities
Huntsville, Alabama • Northport, Alabama • Phoenix, Arizona + 17 more
Conditions
Postpartum Depression
Interventions
ZULRESSO®
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Culver City, California • Miramar, Florida • Pompano Beach, Florida + 2 more
Conditions
Huntington's Disease
Interventions
SAGE-718
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
29
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more
Conditions
Healthy Volunteer
Interventions
SAGE-904, Placebo, Ketamine
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
21 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Newark, New Jersey
Conditions
Epilepsies, Partial
Interventions
Placebo, 2400mg SPN-804, 1200mg SPN-804
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
23
States / cities
Huntsville, Alabama • Northport, Alabama • Phoenix, Arizona + 20 more
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SPN-810 (18 mg), SPN-810 (36 mg), Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
32
States / cities
Chandler, Arizona • Little Rock, Arkansas • Imperial, California + 29 more
Conditions
ADHD
Interventions
Placebo, 400mg SPN-812, 600mg SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
14
States / cities
Long Beach, California • Colorado Springs, Colorado • Bradenton, Florida + 9 more
Conditions
Tinnitus
Interventions
Brexanolone
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
Atlanta, Georgia • Iowa City, Iowa
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
100mg SPN-812, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
48 Months to 69 Months
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
47
States / cities
Saraland, Alabama • Little Rock, Arkansas • Anaheim, California + 41 more
Conditions
Epilepsy
Interventions
TPM XR
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Sacramento, California • Loxahatchee Groves, Florida • Miami, Florida + 7 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
SPN-810, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
38
States / cities
Culver City, California • Orange, California • Colorado Springs, Colorado + 33 more
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
38
States / cities
Beverly Hills, California • Garden Grove, California • Los Alamitos, California + 33 more
Conditions
Migraine Disorders, Headache Disorders
Interventions
SPN-538, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Parkinson Disease
Interventions
Observational study
Other
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Aliso Viejo, California • Irvine, California • Palo Alto, California + 2 more
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
The Epilepsy Study Consortium
Other
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Miami, Florida • Chicago, Illinois • Baltimore, Maryland + 2 more
Conditions
Parkinson's Disease, Motor Symptoms
Interventions
APOKYN, Physical Therapy
Drug · Behavioral
Lead sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Industry
Eligibility
18 Years to 78 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
12
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Loma Linda, California + 9 more
Conditions
Healthy Volunteer
Interventions
SAGE-718, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Long Beach, California • Berlin, New Jersey
Conditions
Epilepsies, Partial
Interventions
SPN-804O
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 17 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Little Rock, Arkansas • Loxahatchee Groves, Florida • Tampa, Florida + 5 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

NCT05358821
Conditions
Huntington Disease
Interventions
SAGE-718, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Los Alamitos, California • Englewood, Colorado + 10 more
Conditions
Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
Interventions
SAGE-718, SAGE-718-matching Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
37
States / cities
Gilbert, Arizona • Phoenix, Arizona • Lafayette, California + 34 more